(Reuters Health)—In a case series report, researchers describe rapid symptom improvement in three patients with polymyalgia rheumatica (PMR) when high glucose levels were brought down. After glucose was controlled, patients experienced improvement in both symptoms and laboratory measures of PMR without glucocorticoid administration or an increase in glucocorticoid dosage, according to the report in the…
Search results for: osteoporosis
COVID-19, New Research & More: 2 Experts Discuss Scientific Advances in Rheumatology at ACR Convergence 2020
The Year in Review session during ACR Convergence 2020 will address advances in clinical and basic science related to rheumatology, including drug safety, precision medicine, the COVID-19 pandemic and more.
How to Succeed in a Fellowship & Beyond
For most doctors, fellowship training represents the final two to three years of formal medical education, and recognition of the unique opportunities of this time period can help aspiring rheumatologists get the most out of their fellowship. Fellowship training is inherently different than residency training, with less structured time, smaller teams (often consisting of only…
ACR Convergence Offers Quick Reviews of Rheumatology Topics in Shorter, ‘Down & Dirty 30’ Sessions
Here’s a taste of what participants in this year’s virtual annual meeting, ACR Convergence 2020, will have access to during Down & Dirty 30, four 30-minute sessions designed to provide refreshers on specific rheumatology-related topics.
Targeted Vertebral Fracture Assessment
A Canadian study sought to identify individuals at high fracture risk and provide them with pharmacotherapy to prevent fractures. They found the assessment of hip and lumbar dual-energy X-ray absorptiometry scans for vertebral fracture can be useful in the identification of women and men aged 70 years and older who should qualify for anti-osteoporosis treatment…
Denosumab Dosing Delays Tied to Increased Fracture Risk
NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…
A Call to Action to Use the Pandemic to Transform Rheumatic Disease Care
No event in recent history has caused such far-reaching changes within the medical industry as the ongoing COVID-19 pandemic. Similar to its ability to spread indiscriminately—infecting people regardless of age, race or socioeconomic background—the virus is inducing immediate and, likely, permanent changes across the entire spectrum of healthcare. Comfortable routines of healthcare delivery have been…
Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD
Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…
In Memoriam … J. Timothy Harrington, MD, MACR: July 6, 1940–June 23, 2020
June saw the passing of a beloved colleague, mentor and friend to many in the rheumatology community when J. Timothy Harrington, MD, died of pancreatic cancer in his hometown of Madison, Wis. Dr. Harrington trained at Massachusetts General Hospital, the National Institutes of Health National Cancer Institute and UT Southwestern Medical Center, and served on…
Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
NEW YORK (Reuters Health)—In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say. Given the findings, “bone mineral density (BMD) should probably be higher than the current target for discontinuation of bisphosphonate treatment…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 58
- Next Page »